Ivemend

Active Ingredient(s): Fosaprepitant Dimeglumine
FDA Approved: * September 5, 2019
Pharm Company: * TEVA PHARMS USA INC
Category: Nausea & Vomiting

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Ivemend Overview

Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic medication, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved by the U.S. Food and Drug Administration (FDA) on January 25, 2008,[1] and by the European Medicines Agency (EMA) on January 11 of the same year.[2] References .mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser...

Read more Ivemend Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Fosaprepitant

Recent Ivemend Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Fosaprepitant Dimeglumine
  • Capsule: 125mg, 40mg, 80mg, 80mg + 125mg
  • Emulsion: 130mg/18ml (7.2mg/ml)
  • For Suspension: 125mg/kit
  • Injection: 130mg, 150mg/vial
  • Powder: 115mg/vial, 150mg/vial
  • Solution: 125mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Fosaprepitant Dimeglumine or a similar ingredient: (4 results)